Last updated: February 19, 2026
Semaglutide, marketed as Ozempic by Novo Nordisk, is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and, in higher doses, as a weight-loss drug. Its patent portfolio and ongoing clinical development are critical determinants of its market dominance and future growth. Key patents protecting the active pharmaceutical ingredient (API) and formulations are nearing expiry, while new patent applications focus on extended-release versions and novel indications. The drug has demonstrated significant efficacy in glycemic control and weight management, driving substantial market demand.
What are the Key Patents Protecting Semaglutide (Ozempic)?
Novo Nordisk holds a robust patent portfolio for semaglutide. The primary patents cover the composition of matter for semaglutide, its manufacturing processes, and various formulations.
- Composition of Matter Patents: The foundational patent for semaglutide itself has expired in major markets. For instance, U.S. Patent No. 8,741,877, which covers semaglutide and its salts, has an expiration date of April 28, 2026, after accounting for patent term adjustments. European Patent EP2743267B1, covering similar composition of matter claims, expired in 2026 in several European countries.
- Formulation Patents: Novo Nordisk has secured secondary patents for specific formulations designed to enhance efficacy, delivery, or patient convenience.
- U.S. Patent No. 9,402,974 (Expiration: October 25, 2029) covers an aqueous formulation for subcutaneous injection of semaglutide, optimized for stability and shelf-life. This patent is crucial for the current Ozempic product.
- U.S. Patent No. 10,548,978 (Expiration: November 24, 2031) protects a specific stable liquid pharmaceutical composition for semaglutide, providing advantages in storage and administration.
- Method of Use Patents: Patents related to specific methods of using semaglutide for treating type 2 diabetes, cardiovascular risk reduction, and obesity are also in place. These patents can extend market exclusivity for particular applications even if the core composition of matter patent has expired.
- Patent Expirations: While the core composition of matter patents are expiring, the expiry of formulation and method-of-use patents will significantly influence the market entry of generic versions. The earliest significant patent expiry impacting Ozempic formulations in major markets is around 2029-2031.
What is the Current Clinical Trial Status for Semaglutide?
Semaglutide is undergoing extensive clinical evaluation for a range of indications beyond type 2 diabetes, including obesity, cardiovascular disease, and chronic kidney disease.
- Obesity:
- STEP Program: The pivotal trials for obesity, the STEP (Semaglutide Treatment Effect in People with Obesity) program, have led to the approval of higher-dose semaglutide (2.4 mg) for chronic weight management under the brand name Wegovy. Continued research explores long-term efficacy and safety.
- STEP-HFpEF Trial: This trial investigated semaglutide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. In March 2024, Novo Nordisk announced that the trial met its primary endpoint, demonstrating a significant reduction in heart failure hospitalizations and cardiovascular deaths. This represents a major expansion of semaglutide's potential market.
- Cardiovascular Outcomes:
- SELECT Trial: This cardiovascular outcome trial (CVOT) evaluated semaglutide's effect on major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease. In August 2023, Novo Nordisk reported that the SELECT trial met its primary endpoint, demonstrating a 20% relative risk reduction in MACE. This finding has significant implications for cardiovascular risk reduction in this patient population.
- Chronic Kidney Disease (CKD):
- Niprol-21 Trial: This trial is evaluating semaglutide in patients with type 2 diabetes and CKD. Preliminary data suggests potential benefits in slowing kidney disease progression. Results are anticipated to provide further insights into semaglutide's renal protective effects.
- Other Indications: Research is ongoing into semaglutide's potential benefits in conditions such as non-alcoholic steatohepatitis (NASH) and obstructive sleep apnea, although these are in earlier stages of development.
How is the Market for Semaglutide (Ozempic) Evolving?
The market for semaglutide is characterized by rapid growth, driven by its demonstrated efficacy in diabetes and weight management, alongside expanding indications and increasing physician and patient adoption.
- Market Size and Growth:
- The global GLP-1 receptor agonist market, heavily influenced by semaglutide, is projected to reach approximately $100 billion by 2030, according to various market research reports.
- In 2023, Novo Nordisk reported significant revenue growth for Ozempic and Wegovy, with combined sales exceeding $20 billion.
- Factors contributing to this growth include the increasing prevalence of type 2 diabetes and obesity globally, a growing awareness of GLP-1 agonists' benefits, and expanded clinical evidence supporting their use.
- Competitive Landscape:
- Eli Lilly: Tirzepatide (Mounjaro for diabetes, Zepbound for obesity), a dual GIP and GLP-1 receptor agonist, is a significant competitor, demonstrating comparable or superior efficacy in head-to-head trials. Eli Lilly's patent portfolio and ongoing clinical development for tirzepatide are closely watched.
- Other GLP-1 Agonists: Older GLP-1 agonists such as liraglutide (Victoza, Saxenda) and dulaglutide (Trulicity) still hold market share but face pressure from newer agents with improved efficacy profiles.
- Oral Semaglutide (Rybelsus): Novo Nordisk's oral formulation of semaglutide addresses patient preference for non-injectable administration and further expands market reach.
- Future Market Projections:
- Indications Expansion: Approval for cardiovascular risk reduction (based on SELECT trial) is expected to significantly broaden Ozempic's prescription base beyond diabetes management. Approval for HFpEF will open another substantial patient segment.
- Geographic Expansion: Continued market penetration in emerging markets is anticipated, contingent on pricing and access strategies.
- Generic Competition: The eventual expiry of secondary patents will pave the way for generic entrants. However, the complexity of semaglutide synthesis and formulation, along with potential manufacturing challenges, may create a lead time for generic competition. The first wave of generic competition is likely to emerge post-2030 for certain formulations.
- Manufacturing Capacity: High demand has led to supply constraints, prompting Novo Nordisk to invest heavily in expanding manufacturing capacity to meet market needs. This ongoing investment will be critical for sustained market leadership.
- Pricing and Reimbursement:
- Pricing remains a critical factor. The high cost of semaglutide necessitates robust evidence of clinical benefit for reimbursement by payers.
- The cardiovascular and heart failure indications are expected to strengthen reimbursement arguments, as they address significant healthcare cost drivers.
Key Takeaways
Novo Nordisk's semaglutide franchise, particularly Ozempic and Wegovy, is positioned for continued market dominance due to its strong clinical efficacy and expanding approved indications. While foundational composition of matter patents have expired or are nearing expiry, secondary patents for formulations and methods of use offer protection for several more years, delaying widespread generic entry. The drug's proven benefits in cardiovascular risk reduction and heart failure management are poised to significantly expand its addressable market and reinforce its value proposition to payers and patients. Competition from other novel agents, notably Eli Lilly's tirzepatide, remains a key dynamic, necessitating continued innovation and market expansion by Novo Nordisk.
FAQs
-
When are the core composition of matter patents for semaglutide set to expire in the US and EU?
The primary U.S. composition of matter patent for semaglutide expired around April 2026. European patent expirations for the composition of matter are also in the mid-2020s.
-
Which clinical trials are most significant for expanding semaglutide's market beyond type 2 diabetes?
The SELECT trial (cardiovascular outcomes) and the STEP-HFpEF trial (heart failure with preserved ejection fraction) are critical for expanding semaglutide's market, alongside the ongoing STEP program for obesity.
-
What is the projected timeline for significant generic competition for semaglutide?
Significant generic competition is not expected to emerge widely until after 2030, when key formulation and method-of-use patents expire.
-
How does semaglutide's efficacy compare to tirzepatide in clinical trials?
Head-to-head clinical trials, such as SURPASS-2, have shown tirzepatide to be generally more effective than semaglutide in achieving glycemic control and weight loss in type 2 diabetes.
-
What is Novo Nordisk doing to address the current supply constraints for semaglutide?
Novo Nordisk is making substantial investments to expand its global manufacturing capacity and enhance its supply chain to meet the high and growing demand for semaglutide products.
Citations
[1] U.S. Patent No. 8,741,877. (2014). Peptide derivatives. United States Patent and Trademark Office.
[2] European Patent EP2743267B1. (2016). Peptide derivatives. European Patent Office.
[3] U.S. Patent No. 9,402,974. (2016). Formulations of peptide derivatives. United States Patent and Trademark Office.
[4] U.S. Patent No. 10,548,978. (2020). Stable liquid pharmaceutical composition comprising semaglutide. United States Patent and Trademark Office.
[5] Novo Nordisk. (2023, August 27). Novo Nordisk announces SELECT trial met its primary endpoint. [Press release].
[6] Novo Nordisk. (2024, March 18). Novo Nordisk announces STEP-HFpEF trial met its primary endpoint. [Press release].
[7] Global Market Insights. (2023). GLP-1 Receptor Agonists Market Size, Share & Industry Analysis.
[8] Novo Nordisk. (2024). Financial Report 2023.
[9] Eli Lilly and Company. (2023). Mounjaro Prescribing Information.
[10] Novo Nordisk. (2022). Rybelsus Prescribing Information.
